Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yvonne Connolly

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Drug Discovery Today. Technologies|August 15, 2018
Experimental and pK<sub>a</sub> prediction aspects of tautomerism of drug-like moleculesYvonne Connolly Martin
Journal of Computer-Aided Molecular Design|April 30, 2010
Overview of the perspectives devoted to tautomerism in molecular designYvonne Connolly Martin
Journal of Computer-Aided Molecular Design|July 19, 2018
How medicinal chemists learned about log PYvonne Connolly Martin
Journal of Computer-Aided Molecular Design|October 21, 2009
Let's not forget tautomersYvonne Connolly Martin
International Journal of Medicinal Chemistry|May 9, 2015
The Discovery of Novel Selective D1 Dopaminergic Agonists: A-68930, A-77636, A-86929, and ABT-413Yvonne Connolly Martin
Journal of Computer-Aided Molecular Design|February 8, 2011
Why you should read Dr. Cramer's perspectiveYvonne Connolly Martin
Journal of Computer-Aided Molecular Design|March 19, 2010
Tautomerism, Hammett sigma, and QSARYvonne Connolly Martin
Rapid Communications in Mass Spectrometry : RCM|August 15, 2013
Chemically facilitating the generation of diagnostic ions from SUMO(2/3) remnant isopeptidesNavin Chicooree, John R Griffiths, Yvonne Connolly, et al.
BMC Bioinformatics|February 27, 2008
Exon level integration of proteomics and microarray dataDanny A Bitton, Michał J Okoniewski, Yvonne Connolly, et al.
Nature Cell Biology|June 12, 2012
The S. pombe cytokinesis NDR kinase Sid2 activates Fin1 NIMA kinase to control mitotic commitment through Pom1/Wee1Agnes Grallert, Yvonne Connolly, Duncan L Smith, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Drug Discovery Today. Technologies|August 15, 2018
Experimental and pK<sub>a</sub> prediction aspects of tautomerism of drug-like moleculesYvonne Connolly Martin
Journal of Computer-Aided Molecular Design|April 30, 2010
Overview of the perspectives devoted to tautomerism in molecular designYvonne Connolly Martin
Journal of Computer-Aided Molecular Design|July 19, 2018
How medicinal chemists learned about log PYvonne Connolly Martin
Journal of Computer-Aided Molecular Design|October 21, 2009
Let's not forget tautomersYvonne Connolly Martin
International Journal of Medicinal Chemistry|May 9, 2015
The Discovery of Novel Selective D1 Dopaminergic Agonists: A-68930, A-77636, A-86929, and ABT-413Yvonne Connolly Martin
Journal of Computer-Aided Molecular Design|February 8, 2011
Why you should read Dr. Cramer's perspectiveYvonne Connolly Martin
Journal of Computer-Aided Molecular Design|March 19, 2010
Tautomerism, Hammett sigma, and QSARYvonne Connolly Martin
Rapid Communications in Mass Spectrometry : RCM|August 15, 2013
Chemically facilitating the generation of diagnostic ions from SUMO(2/3) remnant isopeptidesNavin Chicooree, John R Griffiths, Yvonne Connolly, et al.
BMC Bioinformatics|February 27, 2008
Exon level integration of proteomics and microarray dataDanny A Bitton, Michał J Okoniewski, Yvonne Connolly, et al.
Nature Cell Biology|June 12, 2012
The S. pombe cytokinesis NDR kinase Sid2 activates Fin1 NIMA kinase to control mitotic commitment through Pom1/Wee1Agnes Grallert, Yvonne Connolly, Duncan L Smith, et al.
Pageof 4